Petersfield, Hampshire, October 3rd 2022, Aspire Pharma Limited, today announced the successful completion of its acquisition of Morningside Pharmaceuticals (Loughborough), Morningside Healthcare (Leicester) and Morningside Healthcare (India) (together referred to as “Morningside”); privately owned, speciality generic pharmaceutical organisations.
Morningside delivers Aspire added talent, increased in-market range, and an industry leading pipeline, complementary to Aspire’s. The acquisition establishes Aspire as a premier Speciality Pharma organisation in the UK, with new opportunities to support international growth ambitions.
“We are excited to welcome the Morningside team to the Aspire family. This is a transformative opportunity for both companies to expand and enhance our market position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally. Our commitment remains with our team, patients, and our partners in the NHS and beyond, to ensure a smooth integration of businesses” said Richard Condon, Chief Executive Officer of Aspire Pharma.
“Aspire’s acquisition of Morningside is validation of the long-term growth plan that the shareholders and management of Morningside Pharmaceuticals and Morningside Healthcare have developed over the past 30 years. The combined company will benefit across several areas, including the realisation of enhanced business development capabilities with over 120 complementary mid and late-stage programs” said Tim Brady, Chief Executive Officer, Morningside.
Respective organisations will continue to operate as standalone businesses until further integration and transition announcements are made.
More information can be found at www.aspirepharma.co.uk/morningside
www.morningsidepharm.com/aspire
www.morningsidehealthcare.com/aspire